Treating Plasmodium vivax malaria in Peru

The recruitment of patients for the Partnership for Vivax Elimination (PAVE) study recently started in Peru. This study aims to assess the feasibility, acceptability, and cost implications of administering primaquine or tafenoquine after G6PD testing in real-world settings in Loreto.

In this video, Dr Alejandro Llanos from the Universidad Peruana Cayetano Heredia (UPCH), the study's principal investigator, underscores the importance of providing scientific evidence on the use of these new tools to achieve the goal of eliminating malaria within the country.